Chromocell Therapeutics Corporation (CHRO)
NYSEAMERICAN: CHRO · Real-Time Price · USD
0.576
-0.043 (-6.98%)
Nov 21, 2024, 2:25 PM EST - Market open
Chromocell Therapeutics Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
| TTM
| FY 2023 | FY 2022 | FY 2021 | FY 2020 |
| Sep '24 Sep 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
| Revenue | - | - | - | - | 0.2 |
| Cost of Revenue | 2.58 | 2.58 | 0.39 | 0.21 | 0.14 |
| Gross Profit | -2.58 | -2.58 | -0.39 | -0.21 | 0.06 |
| Selling, General & Admin | 6.44 | 4.28 | 1.93 | 0.63 | 1.42 |
| Operating Expenses | 7.05 | 4.28 | 1.93 | 0.63 | 1.42 |
| Operating Income | -9.63 | -6.86 | -2.32 | -0.84 | -1.35 |
| Interest Expense | -0.84 | -0.52 | -0.14 | -0 | -0 |
| Other Non Operating Income (Expenses) | 0.4 | - | - | - | 0.69 |
| EBT Excluding Unusual Items | -10.07 | -7.38 | -2.46 | -0.84 | -0.66 |
| Other Unusual Items | - | - | - | 0.24 | - |
| Pretax Income | -10.07 | -7.38 | -2.46 | -0.6 | -0.66 |
| Net Income | -10.07 | -7.38 | -2.46 | -0.6 | -0.66 |
| Net Income to Common | -10.07 | -7.38 | -2.46 | -0.6 | -0.66 |
| Shares Outstanding (Basic) | 5 | 1 | 0 | - | - |
| Shares Outstanding (Diluted) | 5 | 1 | 0 | - | - |
| Shares Change (YoY) | 333.40% | 193.25% | - | - | - |
| EPS (Basic) | -2.20 | -5.78 | -5.65 | - | - |
| EPS (Diluted) | -2.20 | -5.78 | -5.65 | - | - |
| Free Cash Flow | -5.48 | -0.98 | -1.57 | -1.59 | -3.63 |
| Free Cash Flow Per Share | -1.20 | -0.77 | -3.60 | - | - |
| Gross Margin | - | - | - | - | 30.68% |
| Operating Margin | - | - | - | - | -677.16% |
| Profit Margin | - | - | - | - | -330.40% |
| Free Cash Flow Margin | - | - | - | - | -1813.48% |
| EBITDA | - | - | -1.63 | - | - |
| D&A For EBITDA | - | - | 0.69 | - | - |
| EBIT | -9.63 | -6.86 | -2.32 | -0.84 | -1.35 |
| Revenue as Reported | - | - | - | - | 0.2 |
Source: S&P Capital IQ. Standard template.
Financial Sources.